Testing epigenetic and sensitizer treatment for AML and MDS
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This early-phase trial tests whether a combination of targeted medicines can improve outcomes in people with higher-risk MDS or certain types of AML or CMML. It’s designed to find the safest dose and learn if the treatment can help the cancer respond.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 or older.
- You have one of these diagnoses: higher-risk MDS, or AML with 20–30% marrow blasts, or CMML with 10–29% marrow blasts (confirmed by a bone marrow test).
- Your general condition is good enough for treatment (ECOG score 0–1).
- Your doctors do not think an allogeneic stem cell transplant (using a donor) is suitable for you.
- You can safely use birth control if you could become pregnant (and take a pregnancy test if needed), and you agree to the study’s sperm/partner contraception rules if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests whether combining two “epigenetic” medicines—azacitidine and decitabine—can improve outcomes for certain bone marrow cancers. It may help if you have a type of myelodysplastic syndrome (MDS) or MDS/MPN overlap that is expected to be sensitive to these medicines.
This trial is testing new drug combinations for people with newly diagnosed, high-risk AML who have not yet started treatment. It aims to find more effective therapies for this aggressive form of leukemia.
This trial tests a strong chemotherapy and radiation combo followed by a donor stem cell transplant for people with aggressive blood cancers (like AML or MDS) that haven't responded to earlier treatments or came back. It aims to help prevent the cancer from returning.
This Phase 1 trial tests CYAD-02 to find the safest and recommended dose for people with AML or MDS that has returned or did not respond to prior treatment. It may help if you have limited treatment options, but participation also requires meeting specific heart, lung, and lab safety requirements.
This Phase 1/2 trial tests a combination of medicines (decitabine/cedazuridine, venetoclax, and ivosidenib or enasidenib) in people with acute myeloid leukemia (AML) that has come back or hasn’t responded. It may help control the leukemia by targeting cancer cells and specific genetic changes in the leukemia.
This Phase 1 trial studies how a pill form of decitabine/cedazuridine behaves in the body and how safe it is for people whose livers don’t work normally. It may help doctors better understand dosing and safety in patients with hepatic impairment.
Hear when a new Myelodysplastic Syndromes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.